316152-95-1

Basic information

• Product Name: (9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate
• Synonyms: (9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate
• CAS NO: 316152-95-1
• Molecular Weight: 529.636
• Mol File: 316152-95-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate(316152-95-1)
• EPA Substance Registry System: (9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate(316152-95-1)

Safety Data

• Hazardous Substances Data: 316152-95-1(Hazardous Substances Data)

Upstream product

• 125238-99-5 (S)-4-tert-butoxycarbonylamino-2-(9H-fluoren-9-ylmethoxycarbonylamino)butyric acid 
• 100-46-9 benzylamine 

Downstream Products

• 315203-42-0 C₂₆H₂₇N₃O₃ 
• 2387-23-7 1,3-Dicyclohexylurea 
• 315203-40-8 tert-butyl ((S)-3-((S)-2-amino-3-(3,4-difluorophenyl)propanamido)-4-(benzylamino)-4-oxobutyl)carbamate 
• 456527-46-1 (S)-2-amino-N-benzyl-4-(N'-Boc-amino)butanamide 

Relevant articles and documents

Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells

Several classes of ligands for Protease-Activated Receptors (PARs) have shown impressive anti-inflammatory and cytoprotective activities, including PAR2 antagonists and the PAR1-targeting parmodulins. In order to support medicinal chemistry studies with hundreds of compounds and to perform detailed mode-of-action studies, it became important to develop a reliable PAR assay that is operational with endothelial cells, which mediate the cytoprotective effects of interest. We report a detailed protocol for an intracellular calcium mobilization assay with adherent endothelial cells in multiwell plates that was used to study a number of known and new PAR1 and PAR2 ligands, including an alkynylated version of the PAR1 antagonist RWJ-58259 that is suitable for the preparation of tagged or conjugate compounds. Using the cell line EA.hy926, it was necessary to perform media exchanges with automated liquid handling equipment in order to obtain optimal and reproducible antagonist concentration-response curves. The assay is also suitable for study of PAR2 ligands; a peptide antagonist reported by Fairlie was synthesized and found to inhibit PAR2 in a manner consistent with reports using epithelial cells. The assay was used to confirm that vorapaxar acts as an irreversible antagonist of PAR1 in endothelium, and parmodulin 2 (ML161) and the related parmodulin RR-90 were found to inhibit PAR1 reversibly, in a manner consistent with negative allosteric modulation.

SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS

The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.

Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: Potent, selective peptide mimetics based on indole and indazole templates [2]

-